User:Mr. Ibrahem/Vutrisiran

Vutrisiran, sold under the brand name Amvuttra, is a medication used to treat polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis. It is used in adults who are still able to walk. It is used by injection under the skin.

Common side effects include joint pain, shortness of breath, and vitamin A deficiency. Vitamin A supplements are recommended. It is a small interfering RNA (siRNA) that decreases expression of the transthyretin (TTR) gene.

Vutrisiran was approved for medical use in the United States and Europe in 2022. In the United States it costs about 244,000 USD per dose. It is made by Alnylam Pharmaceuticals.